Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.

ABSTRACT:

Purpose

COPD exacerbations are associated with worsening clinical outcomes and increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary innervation of the lung, has been developed to reduce clinical consequences of cholinergic hyperactivity and its impact on COPD exacerbations. The AIRFLOW-2 study assessed the durability of safety and efficacy of TLD additive to optimal drug therapy compared to sham bronchoscopy and optimal drug therapy alone in subjects with moderate-to-severe, symptomatic COPD two years post randomization.

Patients and methods

TLD was performed in COPD patients (FEV₁ 30-60% predicted, CAT≥10 or mMRC≥2) in a 1:1 randomized, sham-con

SUBMITTER: Valipour A 

PROVIDER: S-EPMC7652218 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature